Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INSYS rises on FDA OK of fentanyl breakthrough cancer pain spray

This article was originally published in Scrip

Executive Summary

Shares of INSYS Therapeutics climbed as high as 36.4% on 5 January after the US FDA approved Subsys fentanyl sublingual spray as a treatment for breakthrough cancer pain in adults already receiving and tolerant to opioid therapy for their underlying persistent cancer pain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC015800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel